Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Appointed director
Quarterly results
CC transcript
|
|
Larimar Therapeutics, Inc. (ZFGN)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 03/04/2021 |
8-K/A
| Quarterly results |
| 11/12/2020 |
8-K/A
| Financial Statements and Exhibits |
| 09/29/2020 |
8-K/A
| Quarterly results |
| 08/14/2020 |
8-K/A
| Quarterly results |
| 06/26/2020 |
8-K/A
| Other Events, Financial Statements and Exhibits|
Docs:
|
"8-K/A",
"Consent of PricewaterhouseCoopers LLP, the Company's independent registered public accounting firm",
"Management's Discussion and Analysis of Financial Condition and Results of Operations of the Chondrial as of March 31, 2020 and for the three month periods ended March 31, 2020 and 2019",
"Risk Factors of the Company",
"Audited financial statements of Chondrial as of and for the years ended December 31, 2019 and 2018",
"Unaudited condensed consolidated financial statements of Chondrial as of March 31, 2020 and for the three month periods ended March 31, 2020 and 2019",
"Unaudited pro forma condensed combined financial statements of the Company and Chondrial as of and for the three month period ended March 31, 2020 and for the year ended December 31, 2019" |
|
|
|